Muscle & nerve · 2009
Danon disease: further clinical and molecular heterogeneity.
Клинический случайСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sabourdy Frédérique, Michelakakis Helen, Anastasakis Aris, Garcia Virginie, Mavridou Irene, Nieto Michèle, Pons Marie-Claude, Skiadas Constantinos, Moraitou Marina, Manta Panagiota, Elleder Milan, Levade Thierry
Аннотация
Two families of Greek patients with subclinical to severe cardiomyopathy are presented. The diagnosis of Danon disease was supported by a total lack of LAMP2 immunostaining in cultured skin fibroblasts and muscle biopsies. The LAMP2 mutation carried by one patient (c.928G>A) has already been reported but with different symptoms. The second patient had a novel point deletion. This has not been described previously, but it could be detected easily by restriction analysis. This mutation was also found in the patient's brother, and it was associated with severe cardiomyopathy leading to heart failure. Surprisingly, the proband also had partial reduction of alpha-galactosidase A activity, despite the absence of characteristic clinical features of Fabry disease. A substitution in the GLA gene (c.937G>T) was found, and its involvement in the cardiac disease is discussed.
Предметные рубрики MeSH
Amino Acid SubstitutionBase SequenceCardiomyopathiesCells, CulturedChildChild, PreschoolDNA Mutational AnalysisExonsFemaleGene DeletionGenetic MarkersGenetic Predisposition to DiseaseGenotypeGlycogen Storage Disease Type IIbHumansIntronsLysosomal-Associated Membrane Protein 2Lysosomal Membrane ProteinsMaleMutationPedigreealpha-Galactosidase